Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, August 1, 2023
[ Tue, Aug 01st 2023
] - WOPRAI
[ Tue, Aug 01st 2023
] - WOPRAI
[ Tue, Aug 01st 2023
] - WOPRAI
[ Tue, Aug 01st 2023
] - WOPRAI
[ Tue, Aug 01st 2023
] - WOPRAI
[ Tue, Aug 01st 2023
] - WOPRAI
[ Tue, Aug 01st 2023
] - WOPRAI
[ Tue, Aug 01st 2023
] - WOPRAI
[ Tue, Aug 01st 2023
] - WOPRAI
[ Tue, Aug 01st 2023
] - WOPRAI
[ Tue, Aug 01st 2023
] - WOPRAI
[ Tue, Aug 01st 2023
] - WOPRAI
[ Tue, Aug 01st 2023
] - WOPRAI
[ Tue, Aug 01st 2023
] - WOPRAI
[ Tue, Aug 01st 2023
] - WOPRAI
[ Tue, Aug 01st 2023
] - WOPRAI
[ Tue, Aug 01st 2023
] - WOPRAI
[ Tue, Aug 01st 2023
] - WOPRAI
[ Tue, Aug 01st 2023
] - WOPRAI
[ Tue, Aug 01st 2023
] - WOPRAI
[ Tue, Aug 01st 2023
] - WOPRAI
[ Tue, Aug 01st 2023
] - WOPRAI
[ Tue, Aug 01st 2023
] - WOPRAI
[ Tue, Aug 01st 2023
] - WOPRAI
[ Tue, Aug 01st 2023
] - WOPRAI
[ Tue, Aug 01st 2023
] - WOPRAI
[ Tue, Aug 01st 2023
] - WOPRAI
[ Tue, Aug 01st 2023
] - WOPRAI
[ Tue, Aug 01st 2023
] - WOPRAI
[ Tue, Aug 01st 2023
] - WOPRAI
Raghuram Selvaraju Maintained (URGN) at Strong Buy with Increased Target to $54 on, Aug 1st, 2023
Raghuram Selvaraju of HC Wainwright & Co., Maintained "UroGen Pharma Ltd." (URGN) at Strong Buy with Increased Target from $23 to $54 on, Aug 1st, 2023.
Raghuram has made no other calls on URGN in the last 4 months.
There are 2 other peers that have a rating on URGN. Out of the 2 peers that are also analyzing URGN, 1 agrees with Raghuram's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Paul Choi of "Goldman Sachs" Maintained at Hold with Increased Target to $18 on, Monday, July 31st, 2023
This is the rating of the analyst that currently disagrees with Raghuram
- Leland Gershell of "Oppenheimer" Reiterated at Buy and Held Target at $22 on, Monday, May 15th, 2023
